ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

ProQR Therapeutics NV

02/05/2025 13:58

ProQR Therapeutics NV PRQR.OQ PRQR.O is expected to show a rise in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

The Leiden Zuid-holland-based  company is expected to report a 1.3% increase in revenue to €4.506 million from €4.45 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 9 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 1.5% in the last three months. ​

Wall Street's median 12-month price target for ProQR Therapeutics NV is $10.50​, above​ its last closing price of $1.72. ​​​

Previous quarterly performance (using preferred earnings measure in euros). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.11
-0.09
-0.09
Met
-1.7
Sep. 30 2024
-0.10
-0.11
-0.10
Beat
5.2
Jun. 30 2024
-0.11
-0.12
-0.03
Beat
75.9​
Mar. 31 2024
-0.12
-0.11
-0.09
Beat
17.8
​​Dec. 31 2023
-0.10
0.01
-0.07
Missed
-745.2
Sep. 30 2023
-0.10
-0.09
-0.07
Beat
17.8​
Jun. 30 2023
-0.11
-0.11
-0.10
Beat
10
Mar. 31 2023
-0.09
-0.12
-0.11
Beat
6.5

This summary was machine generated May 2 at 12:58 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)